The role of the Administration, Advocacy, Planning and Communication (AAPC) Core is to coordinate and integrate the multiple components of the Dana-Farber/Harvard Breast SPORE and to provide scientific, administrative, and fiscal oversight of the SPORE Projects, Cores, and the Developmental Research and Career Development Award Programs. Administration: The infrastructure for fiscal oversight, including cost centers, financial standards, accounting practices and reporting, will be handled by the administrative personnel in the AAPC Core. Research agreements with all institutions, purchasing, payroll functions, on-line financial reporting and pre- and post-award monitoring and reporting will be coordinated by this Core. Advocacy: The AAPC Core will coordinate and prioritize the work of our large and highly interactive Patient Advocacy Committee. Optimizing the engagement of patient advocates in the research and core work of the Breast SPORE is a significant aim of this Core. Scientific Leadership and Planning: The AAPC Core will provide rigorous scientific leadership and oversight for all of the SPORE Projects, Career Development and Developmental Research Programs. The AAPC Core will organize regular meetings of the Breast SPORE External Advisory Board (EAB) and Internal Advisory Board (IAB). Ad hoc committees will be convened as needed. Written feedback from the EAB and IAB will be provided to the projects at the conclusion of the meetings. Communication: Collaboration is critical to the research conducted in the SPORE, and collaboration cannot occur without effective communication. The AAPC Core will promote communication within the SPORE, between SPORE investigators and the Dana-Farber/Harvard Cancer Center (DF/HCC), across institutions and across SPOREs. To do this, the AAPC Core will coordinate a series of regular meetings including a monthly Research-in-Progress seminar, a weekly Breast Oncology Seminar Series (BOSS) (co-sponsored with the Breast Oncology Center at Dana-Farber Cancer Institute), and an Annual Spring Symposium cosponsored with the DF/HCC Breast and Gynecologic Oncology Programs. Additionally, the Core will organize travel to the NCI-sponsored meetings for SPOREs and encourage participation in other NCI and the DF/HCC meetings, workshops, roundtable events or retreats.

Public Health Relevance

The Administration, Advocacy, Planning and Communication Core will coordinate and manage the research Projects, Core resources, developmental funds and educational activities of the Breast SPORE. This coordination and management will support SPORE investigators in achieving the translational aims outlined in the Projects and Cores, with a focus on preventing breast cancer and improving the outcome of patients who have breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA168504-01A1
Application #
8607757
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (O1))
Project Start
2013-09-17
Project End
2018-07-31
Budget Start
2013-09-17
Budget End
2014-07-31
Support Year
1
Fiscal Year
2013
Total Cost
$253,778
Indirect Cost
$101,942
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Spangle, Jennifer M; Dreijerink, Koen M; Groner, Anna C et al. (2016) PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Rep 15:2692-704
Montaser-Kouhsari, Laleh; Knoblauch, Nicholas W; Oh, Eun-Yeong et al. (2016) Image-guided Coring for Large-scale Studies in Molecular Pathology. Appl Immunohistochem Mol Morphol 24:431-5
Morganella, Sandro; Alexandrov, Ludmil B; Glodzik, Dominik et al. (2016) The topography of mutational processes in breast cancer genomes. Nat Commun 7:11383
Cheng, H; Liu, P; Ohlson, C et al. (2016) PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene 35:2961-70
Choi, Young Eun; Meghani, Khyati; Brault, Marie-Eve et al. (2016) Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep 14:429-39
Ni, Jing; Ramkissoon, Shakti H; Xie, Shaozhen et al. (2016) Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med 22:723-6
Wang, Q; Liu, P; Spangle, J M et al. (2016) PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene 35:3607-12
Nik-Zainal, Serena; Davies, Helen; Staaf, Johan et al. (2016) Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534:47-54
Smid, Marcel; Rodríguez-González, F Germán; Sieuwerts, Anieta M et al. (2016) Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat Commun 7:12910
Johnson, Shawn F; Cruz, Cristina; Greifenberg, Ann Katrin et al. (2016) CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep 17:2367-2381

Showing the most recent 10 out of 38 publications